New Aspects of Helicobacter pylori Infection Involvement in Gastric Oncogenesis

Journal of Surgical Research

Volumn 146, Issue 1, 2008, Pages 149-158

  Kountouras, Jannis ^a   Zavos, Christos ^a   Chatzopoulos, Dimitrios ^a   Katsinelos, Panagiotis ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

apoptosis; epidemiology; gastric cancer; H. pylori; microsatellite instability; oncogenes; tumor suppressor genes

Indexed keywords

CATENIN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 8; PROTEIN P53; SCATTER FACTOR RECEPTOR; UVOMORULIN;

ANGIOGENESIS; ATROPHIC GASTRITIS; BLOOD PRESSURE; CARCINOGENESIS; CELL ADHESION; COLON POLYPOSIS; ENVIRONMENTAL FACTOR; GENE MUTATION; GENE OVEREXPRESSION; HEART INFARCTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEREDITY; HUMAN; HYPERGASTRINEMIA; MISMATCH REPAIR; NONHUMAN; ONCOGENE C FOS; ONCOGENE C MOS; ONCOGENE C MYC; ONCOGENE C RAF; ONCOGENE RAS; ONCOGENE SRC; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEM CELL; STOMACH ADENOCARCINOMA; STOMACH CANCER; STROKE;

ADENOCARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STEM CELLS; STOMACH NEOPLASMS;

EID: 41149162850     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.06.011     Document Type: Review

References (53)

1. Torrado J., Santisteban A., and Ruiz-Ederra J. Genetic susceptibility to gastric cancer. Hepatogastroenterology 48 (2001) 1544
2. Koh T.J., and Wang T.C. Tumors of the stomach. In: Feldman M., Friedman L.S., and Sleisenger M.H. (Eds). Sleisenger and Fordtran's gastrointestinal and liver disease (2002), Saunders, Philadelphia, PA 829
3. Ford J.M. Inherited susceptibility to gastric cancer: Advances in genetics and guidelines for clinical management. In: Perry M.C. (Ed) (2002), American Society of Clinical Oncology: Educational Book, Alexandria, VA 116
4. Kountouras J., Zavos C., and Chatzopoulos D. New concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology 52 (2005) 1305
5. Mingchao, Devereux T.R., Stockton P., et al. Loss of E-cadherin expression in gastric intestinal metaplasia and later stage p53 altered expression in gastric carcinogenesis. Exp Toxicol Pathol 53 (2001) 237
6. Kountouras J., Boura P., and Lygidakis N.J. New concepts of molecular biology for colon carcinogenesis. Hepatogastroenterology 47 (2000) 1291
7. Fiocca R., Luinetti O., Villani L., et al. Molecular mechanisms involved in the pathogenesis of gastric carcinoma: Interactions between genetic alterations, cellular phenotype and cancer histotype. Hepatogastroenterology 48 (2001) 1523
8. Tamura G. Genetic and epigenetic alterations of tumor suppressor and tumor-related genes in gastric cancer. Histol Histopathol 17 (2002) 323
9. Unger Z., Molnar B., Pronai L., et al. Mutant p53 expression and apoptotic activity of Helicobacter pylori positive and negative gastritis in correlation with the presence of intestinal metaplasia. Eur J Gastroenterol Hepatol 15 (2003) 389
10. Joo Y.E., Sohn Y.H., Joo S.Y., et al. The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer. Korean J Intern Med 17 (2002) 211
11. Shibata A., Parsonnet J., Longacre T.A., et al. CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis 23 (2002) 419
12. Tuccillo C., Cuomo A., Rocco A., et al. Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. J Pathol 207 (2005) 277
13. Wu C.Y., Wang C.J., Tseng C.C., et al. Helicobacter pylori promote gastric cancer cells invasion through a NF-κB and COX-2-mediated pathway. World J Gastroenterol 11 (2005) 3197
14. Chang C.S., Chen W.N., Lin H.H., et al. Increased oxidative DNA damage, inducible nitric oxide synthase, nuclear factor κB expression and enhanced antiapoptosis-related proteins in Helicobacter pylori-infected noncardia gastric adenocarcinoma. World J Gastroenterol 10 (2004) 2232
15. Suriano G., Oliveira C., Ferreira P., et al. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet 12 (2003) 575
16. Ebert M.P., Fei G., Kahmann S., et al. Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 23 (2002) 87
17. Suzuki M., Mimuro H., Suzuki T., et al. Interaction of CagA with Crk plays an important role in Helicobacter pylori-induced loss of gastric epithelial cell adhesion. J Exp Med 202 (2005) 1235
18. Kyrlagkitsis I., and Karamanolis D.G. Genes and gastric cancer. Hepatogastroenterology 51 (2004) 320
19. Konturek P.C., Kania J., Kukharsky V., et al. Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells. J Physiol Pharmacol 54 (2003) 17
20. Wang T.C., Dangler C.A., Chen D., et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 118 (2000) 36
21. Kountouras J., Chatzopoulos D., and Zavos C. Reactive oxygen metabolites and upper gastrointestinal diseases. Hepatogastroenterology 48 (2001) 743
22. Guo X.L., Wang L.E., Du S.Y., et al. Association of cyclooxygenase-2 expression with Hp-cagA infection in gastric cancer. World J Gastroenterol 9 (2003) 246
23. Seo J.H., Kim H., and Kim K.H. Cyclooxygenase-2 expression by transcription factors in Helicobacter pylori-infected gastric epithelial cells: Comparison between HP 99 and NCTC 11637. Ann NY Acad Sci 973 (2002) 477
24. Takafuji V.A., Evans A., Lynch K.R., et al. PGE(2) receptors and synthesis in human gastric mucosa: Perturbation in cancer. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 71
25. Chen J.H., Liu T.Y., Wu C.W., et al. Nonsteroidal anti-inflammatory drugs for treatment of advanced gastric cancer: Cyclooxygenase-2 is involved in hepatocyte growth factor mediated tumor development and progression. Med Hypotheses 57 (2001) 503
26. Shen H., Sun W.H., Xue O.P., et al. Influences of Helicobacter pylori on cyclooxygenase-2 expression and prostaglandinE2 synthesis in rat gastric epithelial cells in vitro. J Gastroenterol Hepatol 21 (2006) 754
27. Al-Marhoon M.S., Nunn S., and Soames E.W. cagA+ Helicobacter pylori induces greater levels of prostaglandin E2 than cagA- strains. Prostaglandins Other Lipid Mediat 73 (2004) 181
28. Wong B.C., Jiang X., Fan X.M., et al. Suppression of RelA/p65 nuclear translocation independent of IκB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 22 (2003) 1189
29. Warner T.D., and Mitchell J.A. Cyclo-oxygenases: New forms, new inhibitors, and lessons from the clinic. FASEB J 18 (2004) 790
30. Churin Y., Al-Ghoul L., Kepp O., et al. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol 161 (2003) 249
31. Amemiya H., Kono K., Mori Y., et al. High frequency of c-Met expression in gastric cancers producing alpha-fetoprotein. Oncology 59 (2000) 145
32. Niki M., Isozaki H., Toyoda M., et al. Serum human hepatocyte growth factor (hHGF) is elevated in patients with metastatic gastric carcinoma. Hepatogastroenterology 46 (1999) 568
33. Kim H.K., Song K.S., Park Y.S., et al. Elevated levels of circulating platelet microparticles. VEGF, IL-6 and RANTES in patients with gastric cancer: Possible role of a metastasis predictor. Eur J Cancer 39 (2003) 184
34. Heidemann J., Ogawa H., Dwinell M.B., et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 278 (2003) 8508
35. Kido S., Kitadai Y., Hattori N., et al. Interleukin 8 and vascular endothelial growth factor-prognostic factors in human gastric carcinomas?. Eur J Cancer 37 (2001) 1482
36. Matsumoto K., Konno H., Tanaka T., et al. Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft. Jpn J Cancer Res 91 (2000) 748
37. Houghton J., Stoicoy C., Normura S., et al. Gastric cancer originating from bone marrow-derived cells. Science 306 (2004) 1568
38. Li H.C., Stoicoy C., Rogers A.B., et al. Stem cells and cancer: Evidence for bone marrow stem cells in epithelial cancers. World J Gastroenterol 12 (2006) 363
39. Kountouras J., Zavos C., and Chatzopoulos D. Pathogenetic links between colorectal neoplasia and Barrett's esophagus. Gastrointest Endosc 64 (2006) 298
40. Schwarz A. Preventive gastrectomy in patients with gastric cancer risk due to genetic alterations of the E-cadherin gene defect. Langenbecks Arch Surg 388 (2003) 27
41. Oliveira C., Seruca R., and Caldas C. Genetic screening for hereditary diffuse gastric cancer. Expert Rev Mol Diagn 3 (2003) 201
42. Hoogerbrugge N., Ligtenberg M.J., Nagengast F.M., et al. Preventieve resectie van erfelijk, diffuus maagcarcinoom. Ned Tijdschr Geneeskd 150 (2006) 2417
43. Palestro G., Pellicano R., Fronda G.R., et al. Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy. World J Gastroenterol 11 (2005) 7131
44. Lee T.L., Leung W.K., Lau J.Y., et al. Inverse association between cyclooxygenase-2 overexpression and microsatellite instability in gastric cancer. Cancer Lett 168 (2001) 133
45. Lim S., Lee H.S., Kim H.S., et al. Alteration of E-cadherin-mediated adhesion protein is common, but microsatellite instability is uncommon in young age gastric cancers. Histopathology 42 (2003) 128
46. Sehouli J., Mustea A., Konsgen D., et al. Polymorphism of IL-1 receptor antagonist gene: Role in cancer. Anticancer Res 22 (2002) 3421
47. El-Omar E.M., Rabkin C.S., Gammon M.D., et al. Increased risk of noncardiac gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124 (2003) 1193
48. Furuta T., El-Omar E.M., Xiao F., et al. Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 123 (2002) 92
49. Peek R.M. Helicobacter pylori and gastroesophageal reflux disease. Curr Treat Options Gastroenterol 7 (2004) 59
50. Kountouras J., Kouklakis G., Chatzopoulos D., et al. Large intestine tumors (LI-Tu) and ultra-short Barrett's esophagus (US-BE). Gut 49 Suppl 3 (2001) A1097
51. Malfertheiner P., Megraud F., O'morain C., et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. Gut 56 (2007) 772
52. Romano M., Ricci V., and Zarrilli R. Mechanisms of disease: Helicobacter pylori-related gastric carcinogenesis-implications for chemoprevention. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 622
53. Fujioka T., Yoshiiwa A., Okimoto T., et al. Guidelines for the management of Helicobacter pylori infection in Japan: Current status and future prospects. J Gastroenterol 42 Suppl 17 (2007) 3